medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Reduced exercise capacity, chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype Long COVID

Durstenfeld et al. CPET Findings >1 year after COVID-19

Matthew S. Durstenfeld[1,2,], Michael J. Peluso[1,3], Punita Kaveti[1,4], Christopher Hill[5], Danny Li[2], Erica Sander[4], Shreya Swaminathan[2], Victor M. Arechiga[2], Scott Lu[3], Sarah A Goldberg[6], Rebecca Hoh[2], Ahmed Chenna,[7] Brandon C. Yee,[7] John W. Winslow,[7] Christos J. Petropoulos,[7] J. Daniel Kelly[6,8,9], David V. Glidden[6], Timothy J. Henrich[10], Jeffrey N. Martin[6], Yoo Jin Lee[11], Mandar A. Aras[1,4], Carlin S. Long[1,4], Donald J. Grandis[1,4], Steven G. Deeks[1,3], Priscilla Y. Hsue[1,2]

1 Department of Medicine, University of California, San Francisco, CA, USA
2 Division of Cardiology, Zuckerberg San Francisco General, San Francisco, CA, USA
3 Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA
4 Division of Cardiology, UCSF Health
5 School of Medicine, University of California, San Francisco, USA
6 Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
7 LabCorp-Monogram Biosciences Inc, South San Francisco, CA USA
8 Institute of Global Health Sciences, University of California, San Francisco, USA
9 F.I. Proctor Foundation, University of California, San Francisco, USA
10 Division of Experimental Medicine, University of California, San Francisco, USA
11 Cardiac and Pulmonary Imaging, Department of Radiology, University of California, San Francisco

Presented in part as a late breaking oral presentation at Conference on Retroviruses and Opportunistic Infections, 2/2022, as an oral presentation at the Heart Rhythm Society in 5/2022, and in full at the American Heart Association Scientific Sessions 11/2022.

Keywords: post-acute sequelae of COVID-19 (PASC); Long COVID; chronotropic incompetence; cardiopulmonary exercise testing (CPET); inflammation

Word Count: 3736

Corresponding author:
Matthew S. Durstenfeld, MD MAS
Division of Cardiology, UCSF at Zuckerberg San Francisco General Hospital
1001 Potrero Avenue, 5G8
San Francisco, CA 94110, USA
Tel: +1 628 206 5562; Fax: +1 628 206 5447
e-mail: matthew.durstenfeld@ucsf.edu
twitter: @durstenfeld

Key Points: Long COVID symptoms were associated with reduced exercise capacity on cardiopulmonary exercise testing more than 1 year after SARS-CoV-2 infection. The most common abnormal finding was chronotropic incompetence. Reduced exercise capacity was associated with early elevations in inflammatory markers.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract

BACKGROUND Mechanisms underlying persistent cardiopulmonary symptoms following SARS-CoV-2 infection (post-acute sequelae of COVID-19 "PASC" or "Long COVID") remain unclear. This study sought to elucidate mechanisms of cardiopulmonary symptoms and reduced exercise capacity using advanced cardiac testing.

METHODS We performed cardiopulmonary exercise testing (CPET), cardiac magnetic resonance imaging (CMR) and ambulatory rhythm monitoring among adults > 1 year after confirmed SARS-CoV-2 infection in Long-Term Impact of Infection with Novel Coronavirus cohort (LIINC; substudy of NCT04362150). Adults who completed a research echocardiogram (at a median 6 months after SARS-CoV-2 infection) without evidence of heart failure or pulmonary hypertension were asked to complete additional cardiopulmonary testing approximately 1 year later. Although participants were recruited as a prospective cohort, to account for selection bias, the primary analyses were as a case-control study comparing those with and without persistent cardiopulmonary symptoms. We also correlated findings with previously measured biomarkers. We used logistic regression and linear regression models to adjust for potential confounders including age, sex, body mass index, time since SARS-CoV-2 infection, and hospitalization for acute SARS-CoV-2 infection, with sensitivity analyses adjusting for medical history.

RESULTS Sixty participants (unselected for symptoms, median age 53, 42% female, 87% non-hospitalized) were studied at median 17.6 months following SARS-CoV-2 infection. On maximal CPET, 18/37 (49%) with symptoms had reduced exercise capacity (peak VO_2<85% predicted) compared to 3/19 (16%) without symptoms (p=0.02). The adjusted peak VO_2 was 5.2 ml/kg/min (95%CI 2.1-8.3; p=0.001) or 16.9% lower actual compared to predicted (95%CI 4.3-29.6; p=0.02) among those with symptoms compared to those without symptoms. Chronotropic incompetence was present among 12/21 (57%) with reduced VO_2 including 11/37 (30%) with symptoms and 1/19 (5%) without (p=0.04). Inflammatory markers (hsCRP, IL-6, TNF-α) and SARS-CoV-2 antibody levels measured early in PASC were negatively correlated with peak VO_2 more than 1 year later. Late-gadolinium enhancement on CMR and arrhythmias on ambulatory monitoring were not present.

CONCLUSIONS We found evidence of objectively reduced exercise capacity among those with cardiopulmonary symptoms more than 1 year following COVID-19, which was associated with elevated inflammatory markers early in PASC. Chronotropic incompetence may explain exercise intolerance among some with cardiopulmonary phenotype Long COVID.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Graphical Abstract



medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abbreviations list: PASC=post-acute sequelae of COVID-19; hsCRP=high sensitivity c-reactive protein; LIINC=Long-term Impact of Infection with Novel Coronavirus; LV=left ventricle; RV=right ventricle; CPET=cardiopulmonary exercise testing; CMR=cardiac magnetic resonance imaging; AHRR=adjusted heart rate reserve; POTS=postural orthostatic tachycardia syndrome;

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Background

Following acute SARS-CoV-2 infection, some individuals experience persistent symptoms of "Long COVID" (LC), a type of post-acute sequelae of COVID-19 (PASC) [1]. By 3-6 months after SARS-CoV-2 infection, cardiac function is generally normal on echocardiogram [2-4], suggesting that other techniques are needed to identify physiologic correlates of symptoms. Cardiac magnetic resonance imaging (CMR) has revealed changes in parametric mapping and late gadolinium enhancement (LGE) suggestive of cardiac inflammation without consistent associations with symptoms or differences from controls [5-9]. Cardiopulmonary exercise testing (CPET) has demonstrated reduced exercise capacity 3-6 months after SARS-CoV-2 infection without consistent patterns of limitations [10], and with limited data beyond 1 year after infection.

We designed the Long-Term Impact of Infection with Novel Coronavirus (LIINC) study (NCT 04362150) to evaluate physical and mental health following SARS-COV-2 infection by including individuals representing the spectrum of acute illness and post-acute-recovery [11]. The purpose of this substudy was to elucidate mechanisms underlying cardiopulmonary symptoms >1 year following SARS-CoV-2 infection by comparing symptomatic and recovered individuals using CMR, CPET, and ambulatory rhythm monitoring, and correlating findings with blood-based markers.

Methods

As previously reported, LIINC is a San Francisco-based post-COVID cohort [11]. After our initial echocardiogram-based study did not reveal cardiac mechanisms of symptoms [2], we amended our protocol to conduct a second visit about 1 year later among participants who

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

completed an echocardiogram visit and were willing to undergo additional cardiopulmonary testing. In this subset, we performed cross-sectional cardiopulmonary testing including CPET, CMR, and ambulatory rhythm monitoring and correlated with already measured biomarkers from prior cohort visits (including at the time of the echocardiogram for troponin, NT-pro-BNP, and hsCRP).

Participants

We invited LIINC participants with PCR-confirmed SARS-CoV-2 infection who completed an echocardiogram study visit to participate in additional cardiopulmonary testing irrespective of symptom status. Those with pregnancy (due to expected changes during pregnancy), cardiac disease (congenital heart disease, heart failure, myocardial infarction, coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery, or other heart surgery), pulmonary disease requiring home oxygen or lung surgery, and musculoskeletal or neurologic conditions that precluded participation in cycler ergometry were excluded. Additionally, those with non-MRI compatible implants or claustrophobia were excluded from CMR; those with eGFR <30 ml/min/1.73m^2 were excluded from gadolinium.

Symptoms

Participants completed a structured interview about medical history, characteristics of acute infection, cardiopulmonary diagnoses, and symptoms within the previous two weeks. We defined cardiopulmonary symptoms as chest pain, dyspnea, or palpitations and symptoms as cardiopulmonary symptoms or fatigue in the 2 weeks preceding the study visit. Consistent with the WHO definition, all classified as symptomatic were >3 months after SARS-CoV-2 infection with new symptoms without alternative cardiopulmonary explanations [12].

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Blood-Based Markers

Participants had venous blood collected and processed for serum and plasma on the day of the echocardiogram. Samples were batch processed for measurement of high-sensitivity troponin I, N-terminal prohormone b-type natriuretic protein. A subset had antibodies and additional markers measured at two earlier time points (<90 days and 90-150 days after infection) including IL-6, IL-10, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFN -γ), and tumor necrosis factor (TNF), and SARS-CoV-2 receptor-binding domain (RBD) immunoglobulin G (IgG). These samples were assayed by Monogram Biosciences using the Quanterix Simoa® platform blinded with respect to patient and clinical information, and assay performance was consistent with manufacturers' specifications [13].

Cardiac Magnetic Resonance Imaging

Multiparametric, sequence-standardized, blinded (technician and reader) cardiac magnetic resonance imaging (CMR) was performed with a 3T system (Premier, General Electric), including assessment of LV and RV size and function, parametric mapping, and late gadolinium enhancement. Measurements were performed by a single reader at a dedicated workstation using Medis (Leiden, Netherlands) and AI-assisted Arterys (San Francisco, CA) under supervision of a senior cardiac imager, both blinded to clinical variables, and in accordance with Society for Cardiovascular Magnetic Resonance recommendations. The full protocol is described in Supplemental Methods.

Cardiopulmonary Exercise Testing

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Noninvasive CPETs were performed by an exercise physiologist and cardiology nurse practitioner blinded to participant data according to standard protocol using a metabolic cart (Medical Graphics Corporation Ultima CardiO_2) and cycle ergometer (Lode Corival CPET) with continuous 12 lead ECG monitoring (GE CASE) and noninvasive blood pressure and pulse oximetry measurement. After rest ECG, BP and spirometry measurements were taken, participants exercised to symptom limited maximal exertional with work increased in 1-minute steps targeting a 10-minute test. We determined the work increase per 1 minute step based on the expected peak VO_2 from the maximum voluntary ventilation for a goal 10 minute test, rounded to 5 Watts/min increments based on reported exercise (range 10-30 Watts/min) in accordance with guidelines [14]. The full protocol is described in Supplemental Methods.

We evaluated measured peak VO_2 (in ml/kg/min), estimated percent predicted peak VO_2 using the Wasserman equations [15], and classified peak VO_2 <85% predicted as reduced. We defined chronotropic incompetence as peak VO_2 <85% predicted, adjusted heart rate reserve (AHRR) <80% [$(HR_{peak}-HR_{rest})/(220-age-HR_{rest})$], and no alternative explanation for exercise limitation [16]. CPETs were interpreted independently by two cardiologists with discrepancies resolved through consensus.

Ambulatory Rhythm Monitoring

An ambulatory rhythm monitor (Carnation Ambulatory Monitor, BardyDx) was placed on participants' chests. They were instructed wear it for 2 weeks, press the button for symptoms, and record a symptom diary. Monitors were processed according to BardyDx standard procedures, and reports were overread by a cardiologist.

Statistical Analysis

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

To compare participants with and without symptoms, we used logistic regression to estimate adjusted odds ratios of parameters with symptoms and linear regression to estimate adjusted mean differences. Adjusted models included age, sex, time since SARS-CoV-2 infection, hospitalization, and body mass index. Non-normally distributed variables were log-transformed and findings are reported per doubling or 10-fold change. For biomarker data we report unadjusted Pearson's rho correlation coefficients and adjusted linear regression models. For longitudinal data we used mixed effects models with random intercept per patient. We conducted sensitivity analyses considering other symptom definitions and additionally adjusting for potentially relevant medical history (hypertension, diabetes, asthma/COPD, and HIV) and echocardiographic (LV ejection fraction and LV diastolic function) and spirometry parameters (forced vital capacity, forced expiratory volume in 1 second, and maximal voluntary ventilation.

REDCap was used for data entry. Statistical analyses were performed using STATA version 17.1. P values <0.05 were considered statistically significant and were not adjusted for multiple testing. The first author (MSD) had full access to the data and takes responsibility for the integrity of the data and analysis. The study was approved by the UCSF Institutional Review Board (IRB 20-33000). All participants provided written informed consent prior to participation.

Results

Participant Characteristics

60 participants were included. Median age was 53 (IQR 41-59.5), 25 (42%) were female, and 8 (13%) were hospitalized during acute infection (Table 1). Median infection was in June 2020 (IQR March 2020-November 2020), so most participants were infected with the ancestral strain.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Four participants were vaccinated pre-infection ("breakthrough" infections), and 57 (95%) received at least one SARS-CoV-2 vaccine prior to advanced testing.

Symptoms Persist at 18 Months

At visit 1 (median 6 months after infection; echocardiogram visit), 40/60 (67%) reported symptoms and 32/60 (53%) reported cardiopulmonary symptoms. At visit 2 (median 17.6 months; advanced cardiopulmonary testing visit), 38/60 (63%) reported symptoms and 31/60 (52%) reported cardiopulmonary symptoms. Trajectories of individual symptoms were similar (Supplemental Table 1). Self-reported reduced exercise capacity was highly associated with symptoms: 29/33 (88%) reporting reduced exercise capacity also reported other symptoms versus 9/27 (33%) reporting preserved or improved exercise capacity (OR 14.5, 95%CI 3.9-54.1; $p<0.001$).

CPETs were Maximal Tests

Out of 60 participants who attended a CPET visit, 59 completed CPET at a median 17.6 months after infection (IQR 15.8-19.4); one participant was too hypertensive to undergo CPET. Out of 59 CPETs performed, one was excluded due to β-blocker use, two were excluded for submaximal tests with respiratory exchange ratio (RER) <1.05, leaving 56 CPETs for analysis. Three were stopped for hypertensive response (after reaching >100% predicted peak VO_2); all others were symptom-limited maximal tests. No included participants were taking chronotropic medications or antianginals including β-blockers, non-dihydropyridine calcium channel blockers, ivabradine, or long-acting nitrates at the time of CPET.

Exercise Capacity Lower than Predicted and Objectively Reduced Among those with Symptoms

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Peak VO_2 was <85% predicted among 18/37 (49%) with symptoms compared to 3/19 (16%) without symptoms (p=0.02). A 5 ml/kg/min decrease in peak VO_2 was associated with 2.75 times higher odds of symptoms (95%CI 1.39-5.44; p=0.004). Those with symptoms completed less work despite higher perceived effort and similar respiratory exchange ratio (Table 2). Despite reduced exercise capacity among those with symptoms, most CPET parameters were not associated with symptoms (Table 2 and Supplemental Table 2 for additional parameters including rest spirometry & echocardiographic parameters).

As shown in Figure 1 and Table 2, peak VO_2 was 22.7±8.1 and 29.6±7.0 ml/kg/min among those with and without symptoms, respectively, a difference of 6.9 ml/kg/min (95%CI 2.5-11.3; p=0.003) and 92% versus 107% percent predicted (difference 15% predicted, 95%CI; p=0.02). The adjusted difference in peak VO_2 was 5.2 ml/kg/min (95%CI 2.1-8.3; p=0.001), 0.4 L/min (95%CI 0.09 to 0.73; p=0.02), and 16.9% lower predicted (95%CI 4.3-29.6; p=0.02). Results were unchanged in sensitivity analysis adding diabetes and hypertension; the adjusted difference in peak VO_2 was 4.5 ml/kg/min (95%CI 1.40-7.50; p=0.005). Similarly, results were unchanged in sensitivity analyses accounting for diabetes, hypertension, asthma/COPD, and HIV, resting spirometry values, and echocardiographic parameters (adjusted difference 3.9 ml/kg/min, 95%CI 0.6-7.3; p=0.02), but did vary based on symptom classification used (Supplemental Table 3).

Classification of Reduced Exercise Capacity by Pattern of CPET Findings

Among 56 maximal CPETs, 21 (37%) had peak VO_2<85% predicted; no participants had ventilatory limitation, 3 had cardiac limitation, and one had a hypertensive response. Four had findings most consistent with deconditioning/obesity, and one participant's peak VO_2 was 84% predicted with no other abnormalities (possibly deconditioning). Twelve (21% overall, 57% of those with reduced exercise capacity) had chronotropic incompetence. Among those with

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

symptoms, 11/37 (30%) had chronotropic incompetence compared to 1/19 (5%) without symptoms (p=0.04).

Compared to those with peak $VO_2 \geq 85\%$ without an impaired chronotropic response, those with chronotropic incompetence had 49 bpm lower peak heart rate (119 bpm vs 170; 95%CI 40-60; p<0.0001; Figure 2). They completed 100 Watts less work (196 vs 96, 95%CI 49-152; p=0.0005) and had 12.2 ml/kg/min lower peak VO_2 (95%CI 6.5-17.9; p=0.0001). Those with chronotropic incompetence also had reduced HR recovery at 1 minute (7.9 bpm lower, 95%CI 1.3-14.6; p=0.02). In absolute terms, those with chronotropic incompetence generated a mean peak oxygen consumption of 1.59 L/min compared to 2.35 L/min among those with normal exercise capacity (difference 0.76 L/min, 95%CI 0.23 to 1.28; p=0.007); a linear regression model with only rest and peak heart rate explains 54% of the difference in relative oxygen consumption (ml/kg/min) and 34% of the difference in absolute oxygen consumption (L/min).

Normal Cardiac Structure and Function on CMR

Forty-three participants completed CMR, including two without gadolinium (one eGFR<30 and one due to inability to place an IV). CMR demonstrated normal LV and RV volumes and ejection fraction, and only RV volumes were associated with symptoms with smaller RV size associated with higher odds of symptoms (Table 3). No participants had LGE suggestive of myocardial scar, and native T1 and T2 parametric mapping values and ECV were not associated with symptoms. Some participants (10/43, 23%) had trace or small pericardial effusions with no difference by symptoms (p=0.59).

Palpitations are Not Explained by Arrhythmias on Ambulatory Rhythm Monitoring

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Of those included, 38 participants wore and returned an ambulatory rhythm monitor. Lower maximum heart rate, age-predicted maximum heart rate, and adjusted heart rate reserve were all associated with symptoms consistent with our CPET findings (Table 4). One symptomatic individual had a single episode of non-sustained ventricular tachycardia without recorded symptoms or button push; no other clinically significant arrhythmias including atrial fibrillation or atrial flutter were present in either group (Supplemental Table 4). The burden of sinus tachycardia and supraventricular tachycardias was not significantly increased among those with symptoms. Premature ventricular contractions were associated with symptoms, and we could not exclude an association between premature atrial contractions and symptoms (Table 4). Symptomatic individuals pressed the button 3.2 times more often (95%CI 2.1-4.7; p<0.001). Button pushes were mostly during sinus rhythm, sinus tachycardia, or supraventricular ectopy (Supplemental Figure). Results were similar considering only those with palpitations.

Ambulatory Rhythm Monitoring Correlates of Chronotropic Incompetence on CPET

CPET peak HR correlated with maximum sinus HR during ambulatory monitoring (Pearson's r=0.71; p<0.001), with ambulatory peak HR 29 bpm lower among those with chronotropic incompetence (95%CI 13-45; p<0.001). Chronotropic incompetence was associated with 12.6 bpm higher minimum HR (95%CI 3-22; p=0.01) and 59ms lower HR variability by standard deviation n-to-n (95%CI 24-95; p=0.002; Supplemental Table 4). PR intervals were not significantly longer among those with chronotropic incompetence (171ms vs 168ms; p=0.72). One symptomatic individual had 2nd degree Mobitz type 1 (normal finding), and no participants had 2nd degree Mobitz type 2 or 3rd degree heart block.

Markers of Inflammation Early in PASC are Associated with Exercise Capacity and Pericardial Effusions More than 1 Year Later

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Markers of inflammation in the blood (hsCRP, IL-6, TNF) and SARS-CoV-2 RBD IgG level, but not hs-troponin or NT-pro-BNP measured at 3-9 months after infection are negatively correlated with peak VO_2 more than one year after infection (Figure 3). After adjustment, peak VO_2 was 6.2 ml/kg/min lower per doubling of TNF (95%CI 0.6-11.8; p=0.03) and 1.8 ml/kg/min lower per doubling of hsCRP (95%CI 0.8-2.9; p=0.001).

Longitudinal serum biomarkers of inflammation, neurologic injury, and SARS-CoV-2 RBD IgG were measured at <90 days from SARS-CoV-2 acute infection (median 52 days) and between 90-150 days (median 124 days) in 36 participants who underwent CPET (Figure 4), all prior to vaccination. SARS-CoV-2 IgG (2.99-fold higher mean ratio, 95%CI 1.41-6.33; p=0.004) and TNF (1.34-fold higher mean ratio, 95%CI 1.11-1.61; p=0.002) were higher at <90 days among those with reduced exercise capacity. At 90-150 days, only SARS-CoV-2 IgG (2.12-fold higher mean ratio, 95%CI 1.02-4.43; p=0.04) remained statistically significant, although after adjustment it was no longer statistically significant (1.1 ml/kg/min per doubling, 95%CI -0.3 to 2.4; p=0.11). We could not exclude an effect of IL-6 (1.34-fold higher mean ratio, 95%CI 0.92-1.96; p=0.11; adjusted 2.1 ml/kg/min per doubling, 95%CI -0.5-4.6; p=0.11). Except for IL-6, all other biomarkers decreased over time regardless of eventual exercise capacity.

Discussion

We demonstrate that clinically meaningful reductions in objective exercise capacity are associated with LC symptoms more than 1 year after SARS-CoV-2 infection. Our findings suggest that chronotropic incompetence contributes to exercise limitations in LC. We found elevated inflammatory markers and SARS-CoV-2 antibody levels early in PASC are associated with reduced exercise capacity more than a year later. We did not find evidence of myocarditis, cardiac dysfunction, or clinically significant arrhythmias. Finally, our study validates that CPET

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

allows objective measurement of patient-reported exercise intolerance and therefore may be useful for interventional trials of therapeutics for LC.

Connections between Inflammation, Reduced Exercise Capacity, and Autonomic Responses

Our study extends prior findings that inflammatory markers including hsCRP, IL-6, and TNF are negatively correlated with peak VO_2 early after COVID-19 hospitalization [17] to >1 year after infection and those not hospitalized. This correlation may reflect a common cause for inflammation and exercise limitations in PASC (i.e., viral persistence [18], immune activation [19]), or these markers could be on the causal path from infection to symptoms and reduced exercise capacity. Endothelial and coronary microvascular dysfunction occur in PASC [20-23] and are associated with chronotropic incompetence and inflammation [24, 25]. Inflammation may alter autonomic function which could explain reduced exercise capacity and chronotropic incompetence.

Data from animal models support the hypothesis that chronotropy may be related to inflammatory signals and endothelial functions. Apart from COVID-19, IL-6 impairs chronotropic responses to autonomic signaling in mice [26] and may regulate energy allocation during exercise [27]. In addition, IL-6 and TNF impair endothelial function in animal models via increasing oxidative stress and suppressing endothelial nitric oxide synthase pathways [28]. Ideally, clinical trials should evaluate whether anti-inflammatory strategies improve chronotropy and endothelial function, as both impact exercise capacity and risk of cardiovascular disease.

Autonomic Function, Sinus Node Function, and Inflammation in PASC

Altered autonomic function is a possible unifying explanation for our and others' CPET findings in PASC including altered peripheral oxygen extraction [29], preload failure [30-32], and

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

disordered breathing [30]. Orthostatic intolerance, an autonomic symptom, occurs in PASC [33], and skin biopsies suggest small fiber neuropathy in LC-associated postural-orthostatic tachycardia syndrome [34, 35]. Effects on brainstem regulatory regions or the amygdala [36] could also modify autonomic responses to exercise.

An alternative hypothesis is that SARS-CoV-2 could alter sinus node function. Autopsy studied have not specifically examined sinus node tissue for evidence of persistent viral infection of the sinus node [37], but hamster models suggest that SARS-CoV-2 can infect hamster sinoatrial node cells and *in vitro* sinoatrial-like pacemaker cells resulting in altered calcium handling, activated inflammatory pathways, and induced ferroptosis [38]. Sinus node remodeling may reduce sinus node reserve in heart failure [39]. Although we did not find evidence of cardiac fibrosis or sinus node dysfunction, we cannot fully exclude that sinus node dysfunction may contribute to CI. A combination of autopsy studies that specifically examine sinoatrial tissue and clinical studies may be necessary to identify the relevant mechanisms.

Inflammation modifies autonomic and chronotropic responses. Young adults recovering from SARS-CoV-2 have elevated sympathetic activation at rest [40]. Chronic inflammation in other settings is associated with parasympathetic and sympathetic imbalance, chronotropic incompetence and reduced exercise capacity [24, 41]. Thus, chronic inflammation could blunt chronotropy in PASC even without autonomic nervous system or sinus node damage.

Other Studies of PASC using CPET

Our study is consistent with others that have reported lower peak VO_2 among those with PASC compared to recovered individuals mostly at 3-6 months after severe COVID-19, which we summarized in a systematic review and meta-analysis [10]. Our findings build upon earlier

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

studies by (1) demonstrating reduced peak VO_2 and chronotropic incompetence much later after infection (2) including evaluation of cardiac inflammation, structural heart disease and arrhythmias, (3) adjusting for confounders, (4) including recovered persons as comparators, and (5) demonstrating associations with longitudinal biomarkers.

Differences in classification of exercise limitations across CPET studies of PASC may arise from selection bias, confounding, different CPET protocols, and different interpretation algorithms. Deconditioning, which contributes to reduced exercise capacity after any illness, may be misidentified from noninvasive CPET, and has been commonly reported 3-6 months after hospitalization [10]. Although reductions in physical activity after COVID-19 [42] suggest deconditioning contributes, our findings argue against deconditioning as the only explanation for most individuals as deconditioning more commonly demonstrates an accelerated rather than a blunted heart rate response.

Five other studies have also found that chronotropic incompetence contributes to exercise limitations in PASC [32, 42-45]. Chronotropic incompetence may be underestimated in some studies as sensitivity and specificity vary with exercise modality and protocol and including sub-maximal tests or patients on beta-blockers reduces specificity. Diagnosing chronotropic incompetence may have prognostic implications: it is associated with incident cardiovascular disease, sudden death, and all-cause mortality among men without coronary artery disease [46-48].

Impaired peripheral oxygen extraction, best assessed with invasive CPET, may also contribute to exercise limitations in PASC [29], perhaps via changes in autonomic regulation of microcirculatory function [49] or altered metabolism [50]. We did not find differences in VO_2/work slope, a noninvasive correlate of measured oxygen extraction. Although not observed

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

among our participants, dysfunctional (rapid, erratic) breathing and exercise hyperventilation may contribute to dyspnea in PASC [30, 51, 52].

CMR and Ambulatory Rhythm Monitoring Findings

CMR findings suggestive of myocarditis without cardiac dysfunction may be present in the early post-acute period [5, 8, 53]. Consistent with studies at later time points [6, 7], we did not find evidence of abnormal function or LGE, suggesting that myocarditis is unlikely to explain symptoms in most with PASC.

Our findings are consistent with two studies that did not find arrhythmias in early PASC [54, 55]. In contrast to a study in early PASC [56], inappropriate sinus tachycardia was present only in one individual (without symptoms). Therefore, arrhythmias and inappropriate sinus tachycardia are unlikely to explain symptoms among most individuals with PASC.

Implications for Therapy

Investigation into mechanisms of PASC may benefit from proof-of-concept approaches to identify potential therapies. Although vaccination reduces the risk of PASC [57, 58] and the newer circulating variants may be associated with lower risk of Long COVID [59], there is no data regarding whether anti-viral, anti-inflammatory, or anti-coagulant strategies improve exercise capacity in PASC. In chronotropic incompetence separate from COVID-19, chronic supervised exercise is the only intervention demonstrated to improve exercise capacity and surrogates of autonomic function [60-62]. Exercise is an effective treatment for postural orthostatic tachycardia syndrome, which may also be related to post-viral alterations in autonomic responses to stress and occurs in PASC [63, 64]. Reports of post-exertional malaise or

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

symptom exacerbation (PEM/PESE) in PASC overlapping with ME/CFS [65-67] mean exercise-based interventions should be considered with caution. A study of a six-week structured pacing intervention improved physical activity levels and reduced PESE [68], and another study found that supervised exercise may be helpful rather than harmful in PASC [69].

Limitations

The main limitations of this observational study arise from the small sample size, non-probabilistic sampling, and cross-sectional cardiac measures. Secondly, the difference in peak VO_2 was sensitive to the case definition, but our definition is consistent with current consensus definitions [12]. Volunteer bias may result in overestimated prevalence and magnitude of reduced exercise capacity but should not affect classification of limitations. We did not include an uninfected comparator group and nearly all individuals were unvaccinated at the time of initial SARS-CoV-2 infection. Although we excluded those with cardiac disease, adjusted for measured confounders, and conducted sensitivity analyses adjusting for additional confounders, unmeasured residual confounders including pre-COVID fitness remain. Adjustment (in BMI, for example) may not have fully accounted for confounding. Misclassification of exercise limitations could occur since we did not perform invasive CPET, stress echocardiography, stress CMR, or stress ventriculography. Lastly, we lacked contemporaneous biomarker data with CPETs to ascertain whether a transient inflammatory process or ongoing inflammation is more likely.

Conclusions

In conclusion, more than 1 year after pre-vaccine index SARS-CoV-2 infection, reduced exercise capacity on CPET is associated with LC symptoms, chronotropic incompetence, and higher inflammatory markers and antibody levels in the early post-acute period, but not evidence of

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

myocarditis or arrhythmias. Further investigation into mechanisms of cardiopulmonary PASC should include evaluation of inflammatory pathways, chronotropic function, and the autonomic nervous system to identify therapeutic targets.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Acknowledgements: We would like to thank the research participants and the members of the LIINC study team. We would like to thank Dr. Kara Lynch and Dr. Alan Wu for their assistance with measuring cardiac biomarkers and hsCRP. We would also like to acknowledge support from Jeremy Lambert from Quanterix (Billerica, MA) and Patrick Kaiser from BardyDx, a division of Hillrom (Bellevue, Washington). We acknowledge the contributions of the UCSF Clinical and Translational Science Unit.

This study was funded by philanthropic gifts from Charles W. Swanson and the Ed and Pearl Fein Foundation, research grants from the NIH/NLBI including L30 HL159695 and K12 HL143961, and internal funds from the Division of Cardiology at Zuckerberg San Francisco General. This work was assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS Research Institute. MSD is supported by K12HL143961. MJP is supported by K23AI157875. JDK is supported by NIH/NIAID K23AI135037. TJH is supported by NIH/NIAID 3R01A1141003-03S1. PYH is supported by NIH/NAID 2K24AI112393-06. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions:

MSD designed the study, obtained IRB approval, acquired data, analyzed data, interpreted the findings, and wrote the first draft of the manuscript. MJP assisted in study design, participant recruitment, data interpretation, and critical revision of the manuscript. PK and YJL conducted CMR measurements, drafted the MRI methods, and contributed to interpretation of the MRI

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

findings. CH led the ambulatory rhythm monitoring measurements and participated in interpretation of the findings. DL and ES participated in the cardiopulmonary exercise testing measurements, drafting of the CPET methods, CPET interpretation, and provided input on the manuscript. SS and VMA participated in measurements, data management, and revisions of the manuscript. DVG participated in statistical design, analysis and visualization. SL, SAG, and RH participated in participant recruitment, measurement, and data management. AC, BCY, JWW, and CJP participated in biomarker measurement and provided input on drafts of the manuscript. JDK, TJH, and JNM participated in the study design, interpretation of results, and revision of the manuscript. CSL and DJG provided funding and participated in designing the study, interpreting results, and revising the manuscript. SGD and PYH provided funding, oversight, and mentorship for the first two authors and participated in study design, interpretation of results, and critical manuscript revision.

Competing Interests statement: AC, BCY, JWW, and CJP are employees of Monogram Biosciences, Inc., a division of LabCorp. PYH has received modest honoraria from Gilead and Merck and research grant from Novartis unrelated to the submitted work. All other authors report no other competing interests.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Tables:

Table 1: Baseline Characteristics (n=60)

		Symptoms (n=38)	No Symptoms (n=22)
Months since Infection, median (IQR)		17.7 (15.9, 19.4)	17.5 (15.8, 18.6)
Age (years), median (IQR)		50.5 (40, 57)	54.5 (42, 61)
Sex	Male	19 (50%)	16 (73%)
	Female	19 (50%)	6 (27%)
Race/ Ethnicity	Hispanic/Latino	10 (24%)	5 (22%)
	White	26 (63%)	15 (65%)
	Black/African American	2 (5%)	1 (4%)
	Asian	2 (9%)	3 (7%)
BMI (kg/m^2), mean±SD		30.2±7.5	28.1±5.0
Change in BMI from visit 1 to visit 2, mean±SD		1.18±1.4	1.32±2.1
BMI Category	24.9 or less	10 (26%)	7 (32%)
	25 to 29.9	11 (29%)	10 (45%)
	30 to 34.5	9 (24%)	4 (18%)
	35 or greater	8 (21%)	1 (5%)
Medical History	Hypertension	9 (24%)	5 (24%)
	Diabetes	6 (16%)	1 (5%)
	Asthma/COPD	10 (27%)	2 (10%)
	HIV	10 (26%)	6 (27%)
	Autoimmune Disease	3 (8%)	1 (5%)
	Cancer	1 (3%)	1 (5%)
	Kidney Disease	1 (3%)	0 (0%)
	Former or Current Tobacco use	13 (34%)	3 (14%)
Hospitalized (including ICU)		6 (16%)	2 (9%)
ICU		2 (33% hospitalized)	0

Table 1 Legend: Demographic information, past medical history, and severity of acute COVID-19 by hospitalization/ICU status of the participants who underwent advanced cardiopulmonary testing. Abbreviations: BMI=body mass index, ICU=intensive care unit, IQR=Interquartile Range

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

1 **Table 2: Selected Cardiopulmonary Exercise Testing Parameters by Symptom Status (n=56)**

	Measure	Symptoms (n=37)	No Symptoms (n=19)	Adjusted OR (95%CI; p value)	Adjusted Difference (95%CI; p value)
Exercise Capacity	**Peak VO_2, ml/kg/min**	**22.7 ± 8.1**	**29.6 ± 7.0**	**2.75 per -5 ml/kg/min (1.39-5.44; p=0.004)**	**-5.2 (-8.3to -2.1; p=0.001)**
	Peak VO_2, % predicted	**92.0 ± 22.0**	**107.3 ± 22.0**	**1.22 per -5% (1.04-1.43; p=0.01)**	**-17 (-30 to -4.3; p=0.01)**
	Peak VO_2, L/min	**1.9 ± 0.6**	**2.4 ± 0.7**	**1.18 per -0.1/min (1.03-1.37; p=0.02)**	**-0.41 (-0.73 to -0.09; p=0.01)**
	Proportion <85% predicted	**18 (49%)**	**3 (16%)**	**7.97 (1.56 to 40.8; p=0.01)**	--
Ventila-tory	Peak Respiratory Rate	37.5 ± 8.7	40.8 ± 9.7	0.95 (0.88-1.02; p=0.17)	-3.8 (-10.0 to 2.4; p=0.23)
	Breathing Reserve (MVV-V_{Emax})	44.5 (38.3, 59.0)	32.8 (24.0, 44.8)	1.04 (1.00-1.07; p=0.05)	**14.8 (0.7 to 29; p=0.04)**
	Vent. Efficiency (V_E/VCO_2 slope)[a]	27.5 ± 3.7	25.8 ± 3.7	1.18 (0.98-1.44; p=0.09)	2.0 (-0.4 to 4.4; p=0.10)
Peripheral	VO_2 to Work slope	9.9±3.0	10.9±3.5	0.94 (0.76-1.17; p=0.60)	-0.5 (-2.6 to 1.5; p=0.60)
Cardiac	VO_2 pulse, ml/beat	13.1 ± 3.3	15.4 ± 4.5	0.85 (0.69-1.03; p=0.11)	-1.6 (-3.8 to 0.5; p=0.13)
	SBP peak, mm Hg	173.9 ± 31.7	189.2 ± 23.3	0.86 per 5 mm Hg (0.73-1.03; p=0.10)	-13.2 (-31.3 to 4.8; p=0.15)
Heart Rate	Rest, bpm	78.3 ± 14.5	75.2 ± 10.4	1.01 (0.96-1.06; p=0.75)	0.9 (-6.9 to 8.7; p=0.83)
	Peak, bpm	147.2 ± 25.7	154.1 ± 21.7	0.97 (0.94-1.01; p = 0.10)	-9.3 (-21 to 2; p=0.11)
	Peak, % Age Predicted	**86.2 ± 11.9**	**94.1 ± 9.3**	**0.92 (0.85-0.99; p=0.02)**	**-8.5 (-15.2 to -1.8; p=0.02)**
	Adjusted HR Reserve Achieved, %	73.6 ± 22.0	84.9 ± 21.2	0.97 (0.94-1.00; p=0.05)	-12.1 (-24.6 to 0.5; p=0.06)
	HR Recovery at 1 min, bpm	14.4 ± 7.4	14.0 ± 10.0	1.04 (0.95-1.14; p=0.39)	2.0 (-2.9 to 6.9; p=0.42)
Exertion	**Work (Watts)**	**140.8 ± 60.6**	**196.2 ± 68.2**	**1.20 per -10 Watts (1.04 to 1.40; p=0.01)**	**-49.6 (-86.2 to -13.0; p=0.009)**
	Perceived Exertion, Borg Scale 6-20[b]	**16.2 ± 1.8**	**14.9 ± 2.2**	**1.64 (1.05-2.57; p=0.03)**	**1.3 (0.1 to 2.6; p=0.03)**
	Peak Respiratory Exchange Ratio (VCO_2/VO_2)	1.18 (1.12, 1.23)	1.20 (1.12, 1.30)	1.01 per -0.1 (0.48-2.12; p=0.98)	0.03 (-0.09 to 0.02; p=0.23)

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2 Legend: We present both the odds ratios for the association between CPET parameters and symptoms estimated using logistic regression with adjustment for age, sex, time since COVID, hospitalization for acute COVID, BMI category and the estimated adjusted mean differences between those with and without symptoms using linear regression adjusting for the same covariates. Sensitivity analysis incorporating history of hypertension, diabetes, and lung disease had no substantive changes in effect sizes or confidence intervals. [a]VE/VCO_2 slope could not be determined for one participant without symptoms. [b]Borg scale of perceived exertion was assessed every 2 minutes; these represent the last measurement prior to test stopping. **Bold text represents $p<0.05$.** Abbreviations: AT=Anaerobic threshold; bpm=beats per minute; FVC=Forced Vital Capacity; HR=heart rate; DBP=diastolic blood pressure; MVV=maximal voluntary ventilation; SBP=systolic blood pressure; V_D/V_T=Dead space ratio; V_E = minute ventilation; VCO_2=carbon dioxide production; pVO_2=peak oxygen consumption (VO_2); Vent=Ventilatory.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 3. Cardiac Magnetic Resonance Imaging Parameters (n=41) by Symptom Status

Meaning	Parameter	Symptoms (n=25)	No Symptoms (n=18)	Adjusted OR (95%CI; p value)
Months since SARS-CoV-2 Infection, mean±SD		15.9±3.8	15.9±3.9	--
Hematocrit, mean±SD		43.0 ± 3.5	44.5 ± 4.1	0.86 (0.67 to 1.09; p=0.21)
Body Surface Area, m^2		1.95 ± 0.22	1.90 ± 0.16	1.26 per 0.1 m^2 (0.74-2.17; p=0.38)
Left Ventricular Size and Function	LVEDi, ml/m^2	63.6 ± 13.9	69.3 ± 12.3	0.97 (0.91-1.03; p=0.27)
	LVESi, ml/m^2	24.4 ± 6.9	25.3 ± 7.0	1.00 (0.89-1.12; p=0.97)
	LVEF, %	61.8 ± 5.9	63.3 ± 5.8	0.93 (0.82-1.05; p=0.26)
	LV Mass Index, gm/m^2	47.6 ± 7.9	51.6 ± 7.6	0.98 (0.90 to 1.06; p=0.60)
	Stroke Volume, ml[a]	77.2 ± 18.1	84.2 ± 18.1	0.97 (0.93-1.01; p=0.20)
Right Ventricular Size and Function	**RVEDi, ml/m^2**	**65.3 ± 13.5**	**75.6 ± 12.4**	**0.92 (0.86 to 0.99; p=0.02)**
	RVESi, ml/m^2	**27.1 ± 6.4**	**31.3 ± 7.6**	**0.86 (0.75=0.99; p=0.04)**
	RVEF, %	58.9 ± 5.0	58.4 ± 5.0	0.75 (0.86 to 1.14; p=0.93)
Markers of Cardiac Inflammation	T1 Native Mapping, ms	1202 (1141, 1253)	1219 (1153, 1248)	1.00 (0.99-1.00; p=0.51)
	Post-Contrast T1 Mapping Time, ms	603 (507, 634)	624 (577, 655)	1.00 (0.99 to 1.01; p=0.64)
	Extracellular Volume, %	26.7 ± 6.3	24.2 ± 5.3	1.08 (0.92-1.26; p=0.35)
	T2 Native Mapping, ms	46.5 (44.4, 51.0)	48.0 (44.0, 51.4)	0.97 (0.83-1.13; p=0.70)
Cardiac Fibrosis	LGE	0	0	--
Possible Pericardial Inflammation	Pericardial Effusion	6 (24%)	5 (22%)	0.47 (0.08-2.71; p=0.41)

Table 3 Legend: CMR parameters by cardiopulmonary symptoms given as mean±SD or median (intraquartile range) for non-normally distributed variables. Logistic regression was used to estimated odds of having symptoms for a given change in each parameter adjusted for age, sex, BMI category, hospitalization, and time since infection. Only RV end diastolic and end systolic volume indices were associated with symptoms with larger RV size associated with lower odds of symptoms. **Bold text represents p<0.05.** Abbreviations: LVEDi=Left ventricular end diastolic volume indexed to body surface area; LVESi=Left ventricular end diastolic volume indexed to body surface area; LVEF=left ventricular ejection fraction; RVEDi=Right ventricular end diastolic volume indexed to body surface area; RVESi=Right ventricular end diastolic volume indexed to body surface area; RVEF=Right ventricular Ejection Fraction. LGE=Late Gadolinium Enhancement. [a]LV stroke volumes are reported but there is a high correlation between LV and RV stroke volumes (Pearson's r=0.96).

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 4: Ambulatory Rhythm Monitoring Findings by Symptoms (n=38)

Parameter	Symptoms (n=24)	No Symptoms (n=14)	Adjusted OR for symptoms (95%CI; p value)	Adjusted OR for palpitations (95%CI; p value)
Monitoring Time, days	4 (3, 13)	8 (3, 13)	--	
Average Heart Rate, bpm	77.5 ± 11.4	74.4 ± 4.5	1.04 (0.96 to 1.14; p=0.34)	1.11 (0.98-1.28; p=0.11)
Minimum HR, bpm	50.2 ± 12.5	44.9 ± 2.8	1.13 (0.96-1.33; p=0.13)	**1.38 (1.04-1.82; p=0.02)**
Maximum HR, bpm	142.2 ± 19.0	157.4 ± 21.4	**1.77 per -10 (1.03 to 3.03; p=0.04)**	**2.60 (1.07-6.34; p=0.04)**
Maximum HR, % predicted	85.1 ± 9.1	94.9 ± 11.3	**3.39 per -10 (1.09 to 10.6; p=0.04)**	**9.15 (1.14-72.9; p=0.04)**
Adjusted HRR achieved, %	70.7 ± 19.7	89.9 ± 20.1	**1.77 per -10 (1.09 to 2.89; p=0.02)**	**4.20 (1.34-13.2; p=0.01)**
Heart Rate Variability, SDNN	143.5 (113.3, 185.5)	155.7 (137.0, 177.0)	1.00 per -10 (0.87 to 1.16; p=0.97)	**1.91 (1.08-3.60; p=0.03)**
PAC, % burden	0.02 (0.01, 0.10)	0.01 (0.01, 0.04)	1.36 per 10-fold increase (0.58 to 3.20; p=0.48)	1.05 (0.36-3.05; p=0.93)
PVC, % burden	0.01 (0.01, 0.15)	0.01 (0, 0.01)	**2.74 per 10-fold increase (1.14 to 6.53; p=0.02)**	2.20 (0.92-5.31; p=0.08)
Sinus tachycardia, % burden	7 (3, 13)	4 (3, 6)	1.15 (0.97 to 1.37; p=0.12)	1.20 (1.00-1.43; p =0.05)
Episodes of SVT* per week	1.2 (0, 3.5)	0 (0, 3)	1.08 (0.91 to 1.28; p =0.39)	1.15 (0.91-1.46; p=0.25)
Episodes of Nonsustained VT	0	1	--	
Button Pushes	2.5 (0.5,7)	1 (0, 2)	1.33 (1.00-1.76; p=0.05)	1.13 (0.93-1.36; p=0.22)

Table 4 Legend. Values are reported as mean±SD or median (interquartile range) for non-normally distributed variables assessed by histogram. Those with self-reported symptoms pressed the symptom button on the monitor more 3.2 times more often (95%CI 2.1-4.7; p<0.001). **Bolded results are p<0.05.**

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figures:

Figure 1. Exercise Capacity by Symptoms and HR Response to Exercise (n=56)



Figure 1 Legend: Box and whisker plots of peak VO_2 (ml/kg/min in Panel A and percent predicted in Panel B) among those without (blue) and with symptoms (pink) 17.6 months after SARS-CoV-2 infection (top). In Panel C peak VO_2 in ml/kg/min is plotted by adjusted heart rate reserve (AHRR) to demonstrate the cluster of symptomatic individuals with low peak VO_2 and chronotropic incompetence in the bottom left. Panel D demonstrates CPET patterns among those with Long COVID symptoms: half achieved greater than 85% predicted peak VO_2, and chronotropic incompetence was the most common pattern among those with reduced exercise capacity.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 2. Heart Rate during Exercise by Chronotropic Response to Exercise



Figure 2 Legend: Mean heart rate is plotted as a function of exercise time normalized to percent of predicted peak VO_2: in purple are those with normal exercise capacity (peak VO_2 >85% predicted and normal heart rate response (n=16), in teal are those with normal exercise capacity (peak VO2>85%; n=8) and blunted heart rate response (AHRR<80%; n=8), and in yellow are those with chronotropic incompetence (n=9), as described in Supplemental Table 4.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 3. Correlations between Peak VO_2 and Previously Measured Biomarkers



Figure 3 Legend. Scatterplots and linear trend lines of peak VO_2 (measured at ~18 months) by natural log of previously measured biomarker levels with unadjusted Pearson's rho correlations and p-values listed (top row, median 6 months after SARS-CoV-2 infection; bottom two rows median 3.5 months after SARS-CoV-2 infection). Prior hsCRP, IL-6, TNF and SARS-CoV-2 receptor binding domain antibody levels were correlated with subsequent peak VO_2. All antibody levels were measured prior to vaccination.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4. Change in Biomarkers Early Post-Infection by Eventual Exercise Capacity at 18 months (n=35)



Figure 4 Legend: Mean ± standard error of the mean for serum biomarkers over time among those with reduced exercise capacity (red) and preserved exercise capacity (blue) measured at <90 days from SARS-CoV-2 acute infection (median 52 days from symptom onset) and between 90-150 days (median 124 days from symptom onset) in 35 participants who underwent CPET. Inflammatory markers decreased over time, except for IL-6 among those with reduced exercise capacity. MCP-1, TNF, and IgG were higher early among those with reduced exercise capacity. TNF and IgG remained higher and GFAP became lower among those with reduced exercise capacity at the second time point.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

References

1. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-61. Epub 2022/08/08. doi: 10.1016/s0140-6736(22)01214-4. PubMed PMID: 35934007; PubMed Central PMCID: PMCPMC9352274.
2. Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7(10). Epub 2022/04/08. doi: 10.1172/jci.insight.157053. PubMed PMID: 35389890; PubMed Central PMCID: PMCPMC9220849.
3. Fayol A, Livrozet M, Boutouyrie P, Khettab H, Betton M, Tea V, et al. Cardiac performance in patients hospitalized with COVID-19: a 6 month follow-up study. ESC Heart Fail. 2021;8(3):2232-9. Epub 2021/03/28. doi: 10.1002/ehf2.13315. PubMed PMID: 33773099; PubMed Central PMCID: PMCPMC8120370.
4. Tangen J, Aukrust P, Barratt-Due A, Skulstad H, Edvardsen T. Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients >3 Months after Hospitalization. Journal of the American Society of Echocardiography. 2022;35(2):243-4. doi: 10.1016/j.echo.2021.10.014.
5. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020. doi: 10.1001/jamacardio.2020.3557.
6. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, et al. Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. JACC: Cardiovascular Imaging. 2021;14(11):2155-66. doi: doi:10.1016/j.jcmg.2021.04.011.
7. Cassar MP, Tunnicliffe EM, Petousi N, Lewandowski AJ, Xie C, Mahmod M, et al. Symptom Persistence Despite Improvement in Cardiopulmonary Health - Insights from longitudinal CMR, CPET and lung function testing post-COVID-19. EClinicalMedicine. 2021;41:101159. Epub 2021/10/26. doi: 10.1016/j.eclinm.2021.101159. PubMed PMID: 34693230; PubMed Central PMCID: PMCPMC8527025.
8. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866-78. Epub 2021/02/18. doi: 10.1093/eurheartj/ehab075. PubMed PMID: 33596594; PubMed Central PMCID: PMCPMC7928984.
9. Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu E, et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med. 2022;28(10):2117-23. Epub 2022/09/06. doi: 10.1038/s41591-022-02000-0. PubMed PMID: 36064600; PubMed Central PMCID: PMCPMC9556300.
10. Durstenfeld MS, Sun K, Tahir P, Peluso MJ, Deeks SG, Aras MA, et al. Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(10):e2236057. Epub 2022/10/13. doi: 10.1001/jamanetworkopen.2022.36057. PubMed PMID: 36223120.
11. Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infectious Diseases. 2021;9(2). doi: 10.1093/ofid/ofab640.
12. Soriano JM, J; Diaz, JV; Murthy, S;; Relan, P. A clinical case definition of post COVID-19 condition by a Delphi consensus. In: Organization WH, editor. 2021.1 ed: ; 2021.
13. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Syndrome Coronavirus 2 Infection. J Infect Dis. 2021;224(11):1839-48. Epub 2021/10/23. doi: 10.1093/infdis/jiab490. PubMed PMID: 34677601; PubMed Central PMCID: PMCPMC8643408.

14. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191-225. Epub 2010/06/30. doi: 10.1161/CIR.0b013e3181e52e69. PubMed PMID: 20585013.

15. Wasserman K HJ, Sue DY, Stringer W, Whipp BJ. Principles of Exercise Testing and Interpretation. 4th ed. Philadelpha: Lippincott Williams and Wilkins; 2005.

16. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation. 2011;123(9):1010-20. Epub 2011/03/09. doi: 10.1161/CIRCULATIONAHA.110.940577. PubMed PMID: 21382903; PubMed Central PMCID: PMCPMC3065291.

17. Ribeiro Baptista B, d'Humieres T, Schlemmer F, Bendib I, Justeau G, Al-Assaad L, et al. Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort. Respir Res. 2022;23(1):68. Epub 2022/03/24. doi: 10.1186/s12931-022-01977-z. PubMed PMID: 35317815; PubMed Central PMCID: PMCPMC8938727.

18. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022. Epub 2022/09/03. doi: 10.1093/cid/ciac722. PubMed PMID: 36052466.

19. Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 2022;18(5):e1010359. Epub 2022/05/27. doi: 10.1371/journal.ppat.1010359. PubMed PMID: 35617421.

20. Paneroni M, Pasini E, Vitacca M, Scalvini S, Comini L, Pedrinolla A, et al. Altered Vascular Endothelium-Dependent Responsiveness in Frail Elderly Patients Recovering from COVID-19 Pneumonia: Preliminary Evidence. J Clin Med. 2021;10(12). Epub 2021/07/03. doi: 10.3390/jcm10122558. PubMed PMID: 34207876; PubMed Central PMCID: PMCPMC8228458.

21. Mejia-Renteria H, Travieso A, Sagir A, Martínez-Gómez E, Carrascosa-Granada A, Toya T, et al. In-vivo evidence of systemic endothelial vascular dysfunction in COVID-19. International Journal of Cardiology. 2021;345:153-5. doi: https://doi.org/10.1016/j.ijcard.2021.10.140.

22. Drakos S, Chatzantonis G, Bietenbeck M, Evers G, Schulze AB, Mohr M, et al. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci Rep. 2021;11(1):15667. Epub 2021/08/04. doi: 10.1038/s41598-021-95277-z. PubMed PMID: 34341436; PubMed Central PMCID: PMCPMC8329060.

23. Ahmed AI, Saad JM, Han YS, Malahfji M, Nabi F, Mahmarian JJ, et al. Coronary Microvascular Health in Patients with Prior Covid-19 Infection: Implications for Long-Covid Syndrome. Journal of the American College of Cardiology. 2022;79(9):1822-. doi: doi:10.1016/j.jcmg.2022.07.006. PubMed PMID: WOS:000781026602023.

24. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA, et al. Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart. 2006;92(5):609-14. Epub 2005/09/15. doi: 10.1136/hrt.2005.064147. PubMed PMID: 16159987; PubMed Central PMCID: PMCPMC1860951.

25. Bechsgaard DF, Hove JD, Suhrs HE, Bové KB, Shahriari P, Gustafsson I, et al. Women with coronary microvascular dysfunction and no obstructive coronary artery disease have reduced exercise capacity. International Journal of Cardiology. 2019;293:1-9. doi: https://doi.org/10.1016/j.ijcard.2019.07.048.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

26. Hajiasgharzadeh K, Mirnajafi-Zadeh J, Mani AR. Interleukin-6 impairs chronotropic responsiveness to cholinergic stimulation and decreases heart rate variability in mice. Eur J Pharmacol. 2011;673(1-3):70-7. Epub 2011/11/03. doi: 10.1016/j.ejphar.2011.10.013. PubMed PMID: 22044916.

27. Kistner TM, Pedersen BK, Lieberman DE. Interleukin 6 as an energy allocator in muscle tissue. Nat Metab. 2022;4(2):170-9. Epub 2022/02/26. doi: 10.1038/s42255-022-00538-4. PubMed PMID: 35210610.

28. Lee J, Lee S, Zhang H, Hill MA, Zhang C, Park Y. Interaction of IL-6 and TNF-α contributes to endothelial dysfunction in type 2 diabetic mouse hearts. PLoS One. 2017;12(11):e0187189. Epub 2017/11/03. doi: 10.1371/journal.pone.0187189. PubMed PMID: 29095915; PubMed Central PMCID: PMCPMC5667841.

29. Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161(1):54-63. Epub 2021/08/15. doi: 10.1016/j.chest.2021.08.010. PubMed PMID: 34389297; PubMed Central PMCID: PMCPMC8354807.

30. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease. JACC Heart Fail. 2021;9(12):927-37. Epub 2021/12/04. doi: 10.1016/j.jchf.2021.10.002. PubMed PMID: 34857177; PubMed Central PMCID: PMCPMC8629098.

31. Brown JT, Saigal A, Karia N, Patel RK, Razvi Y, Constantinou N, et al. Ongoing Exercise Intolerance Following COVID-19: A Magnetic Resonance-Augmented Cardiopulmonary Exercise Test Study. J Am Heart Assoc. 2022;11(9):e024207. Epub 2022/04/27. doi: 10.1161/JAHA.121.024207. PubMed PMID: 35470679.

32. Szekely Y, Lichter Y, Sadon S, Lupu L, Taieb P, Banai A, et al. Cardiorespiratory Abnormalities in Patients Recovering from Coronavirus Disease 2019. J Am Soc Echocardiogr. 2021;34(12):1273-84.e9. Epub 2021/09/12. doi: 10.1016/j.echo.2021.08.022. PubMed PMID: 34508837; PubMed Central PMCID: PMCPMC8425293.

33. Jamal SM, Landers DB, Hollenberg SM, Turi ZG, Glotzer TV, Tancredi J, et al. Prospective Evaluation of Autonomic Dysfunction in Post-Acute Sequela of COVID-19. Journal of the American College of Cardiology. 2022;79(23):2325-30. doi: doi:10.1016/j.jacc.2022.03.357.

34. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367-79. Epub 2021/12/26. doi: 10.1002/ana.26286. PubMed PMID: 34952975.

35. Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, et al. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3). Epub 2022/03/03. doi: 10.1212/nxi.0000000000001146. PubMed PMID: 35232750; PubMed Central PMCID: PMCPMC8889896.

36. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697-707. Epub 2022/03/08. doi: 10.1038/s41586-022-04569-5. PubMed PMID: 35255491; PubMed Central PMCID: PMCPMC9046077.

37. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758-63. Epub 2022/12/15. doi: 10.1038/s41586-022-05542-y. PubMed PMID: 36517603; PubMed Central PMCID: PMCPMC9749650.

38. Han Y, Zhu J, Yang L, Nilsson-Payant BE, Hurtado R, Lacko LA, et al. SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells. Circ Res. 2022;130(7):963-77. Epub 2022/03/09. doi: 10.1161/CIRCRESAHA.121.320518. PubMed PMID: 35255712; PubMed Central PMCID: PMCPMC8963443.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

39. Sanders P, Kistler PM, Morton JB, Spence SJ, Kalman JM. Remodeling of sinus node function in patients with congestive heart failure: reduction in sinus node reserve. Circulation. 2004;110(8):897-903. Epub 2004/08/11. doi: 10.1161/01.CIR.0000139336.69955.AB. PubMed PMID: 15302799.

40. Stute NL, Stickford JL, Province VM, Augenreich MA, Ratchford SM, Stickford ASL. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. J Physiol. 2021;599(18):4269-85. Epub 2021/06/27. doi: 10.1113/JP281888. PubMed PMID: 34174086; PubMed Central PMCID: PMCPMC8447023.

41. Franssen WMA, Keytsman C, Marinus N, Verboven K, Eijnde BO, van Ryckeghem L, et al. Chronotropic incompetence is more frequent in obese adolescents and relates to systemic inflammation and exercise intolerance. J Sport Health Sci. 2021. Epub 2021/02/03. doi: 10.1016/j.jshs.2021.01.010. PubMed PMID: 33529767.

42. Margalit I, Yelin D, Sagi M, Rahat MM, Sheena L, Mizrahi N, et al. Risk factors and multidimensional assessment of long COVID fatigue: a nested case-control study. Clin Infect Dis. 2022. Epub 2022/04/12. doi: 10.1093/cid/ciac283. PubMed PMID: 35403679.

43. Jimeno-Almazán A, Pallarés JG, Buendía-Romero Á, Martínez-Cava A, Courel-Ibáñez J. Chronotropic Incompetence in Non-Hospitalized Patients with Post-COVID-19 Syndrome. Journal of Clinical Medicine. 2021;10(22):5434. PubMed PMID: doi:10.3390/jcm10225434.

44. Abdallah SJ, Voduc N, Corrales-Medina VF, McGuinty M, Pratt A, Chopra A, et al. Symptoms, Pulmonary Function, and Functional Capacity Four Months after COVID-19. Ann Am Thorac Soc. 2021;18(11):1912-7. Epub 2021/04/20. doi: 10.1513/AnnalsATS.202012-1489RL. PubMed PMID: 33872135; PubMed Central PMCID: PMCPMC8641826.

45. Ladlow P, O'Sullivan O, Houston A, Barker-Davies R, May S, Mills D, et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2022;19(4):613-20. doi: https://doi.org/10.1016/j.hrthm.2021.12.005.

46. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951-8. Epub 2005/05/13. doi: 10.1056/NEJMoa043012. PubMed PMID: 15888695.

47. Savonen KP, Lakka TA, Laukkanen JA, Halonen PM, Rauramaa TH, Salonen JT, et al. Heart rate response during exercise test and cardiovascular mortality in middle-aged men. European Heart Journal. 2006;27(5):582-8. doi: 10.1093/eurheartj/ehi708.

48. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired Chronotropic Response to Exercise Stress Testing as a Predictor of Mortality. JAMA. 1999;281(6):524-9. doi: 10.1001/jama.281.6.524.

49. Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, et al. Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chest. 2021;160(2):642-51. Epub 2021/02/13. doi: 10.1016/j.chest.2021.01.082. PubMed PMID: 33577778; PubMed Central PMCID: PMCPMC8727854.

50. de Boer E, Petrache I, Goldstein NM, Olin JT, Keith RC, Modena B, et al. Decreased Fatty Acid Oxidation and Altered Lactate Production during Exercise in Patients with Post-acute COVID-19 Syndrome. Am J Respir Crit Care Med. 2022;205(1):126-9. Epub 2021/10/20. doi: 10.1164/rccm.202108-1903LE. PubMed PMID: 34665688; PubMed Central PMCID: PMCPMC8865580.

51. Fresard I, Genecand L, Altarelli M, Gex G, Vremaroiu P, Vremaroiu-Coman A, et al. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in 'long COVID' patients with persistent dyspnoea. BMJ Open Respir Res. 2022;9(1):e001126. Epub 2022/04/01. doi: 10.1136/bmjresp-2021-001126. PubMed PMID: 35354589; PubMed Central PMCID: PMCPMC8968537.

52. Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, et al. Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. Eur Respir J.

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2021;58(2):2101578. Epub 2021/08/14. doi: 10.1183/13993003.01578-2021. PubMed PMID: 34385265; PubMed Central PMCID: PMCPMC8361302 support from Servier, outside the submitted work. A. Cohen-Solal has received grants or honoraria from Novartis, Servier, Daiichi Sankyo, Vifor, Menarini and Cardiorentis, outside of the submitted work. J. Frija-Masson reports non-financial support from Vitalaire, Boehringer Ingelheim, Oxyvie and LVL Medical, outside the submitted work. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

53. Morrow AJ, Sykes R, McIntosh A, Kamdar A, Bagot C, Bayes HK, et al. A multisystem, cardio-renal investigation of post-COVID-19 illness. Nat Med. 2022. Epub 2022/05/24. doi: 10.1038/s41591-022-01837-9. PubMed PMID: 35606551.

54. Ingul CB, Grimsmo J, Mecinaj A, Trebinjac D, Berger Nossen M, Andrup S, et al. Cardiac Dysfunction and Arrhythmias 3 Months After Hospitalization for COVID-19. J Am Heart Assoc. 2022;11(3):e023473. Epub 2022/01/21. doi: 10.1161/JAHA.121.023473. PubMed PMID: 35048715.

55. Dewland TA, Whitman IR, Win S, Sanchez JM, Olgin JE, Pletcher MJ, et al. Prospective arrhythmia surveillance after a COVID-19 diagnosis. Open Heart. 2022;9(1). Epub 2022/01/22. doi: 10.1136/openhrt-2021-001758. PubMed PMID: 35058344; PubMed Central PMCID: PMCPMC8783964.

56. Aranyó J, Bazan V, Lladós G, Dominguez MJ, Bisbal F, Massanella M, et al. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Scientific Reports. 2022;12(1):298. doi: 10.1038/s41598-021-03831-6.

57. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine. 2022. doi: 10.1038/s41591-022-01840-0.

58. Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022;13(1):5663. Epub 2022/10/13. doi: 10.1038/s41467-022-33415-5. PubMed PMID: 36224173; PubMed Central PMCID: PMCPMC9556711.

59. Durstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, et al. Factors Associated With Long COVID Symptoms in an Online Cohort Study. Open Forum Infect Dis. 2023;10(2):ofad047. Epub 2023/02/28. doi: 10.1093/ofid/ofad047. PubMed PMID: 36846611; PubMed Central PMCID: PMCPMC9945931.

60. Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ, et al. Effects of exercise training on chronotropic incompetence in patients with heart failure. Am Heart J. 1999;138(2 Pt 1):233-40. Epub 1999/07/30. doi: 10.1016/s0002-8703(99)70106-7. PubMed PMID: 10426833.

61. Kiilavuori K, Toivonen L, Näveri H, Leinonen H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J. 1995;16(4):490-5. Epub 1995/04/01. doi: 10.1093/oxfordjournals.eurheartj.a060941. PubMed PMID: 7671894.

62. Myers J, Hadley D, Oswald U, Bruner K, Kottman W, Hsu L, et al. Effects of exercise training on heart rate recovery in patients with chronic heart failure. Am Heart J. 2007;153(6):1056-63. Epub 2007/06/02. doi: 10.1016/j.ahj.2007.02.038. PubMed PMID: 17540210.

63. Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci. 2018;215:20-7. Epub 2018/07/14. doi: 10.1016/j.autneu.2018.07.001. PubMed PMID: 30001836; PubMed Central PMCID: PMCPMC6289756.

64. George SA, Bivens TB, Howden EJ, Saleem Y, Galbreath MM, Hendrickson D, et al. The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13(4):943-50. Epub 2015/12/23. doi: 10.1016/j.hrthm.2015.12.012. PubMed PMID: 26690066.

65. Bonilla H, Quach TC, Tiwari A, Bonilla AE, Miglis M, Yang PC, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. Front Neurol. 2023;14:1090747. Epub

medRxiv preprint doi: https://doi.org/10.1101/2022.05.17.22275235; this version posted March 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2023/03/14. doi: 10.3389/fneur.2023.1090747. PubMed PMID: 36908615; PubMed Central PMCID: PMCPMC9998690.

66. Jason LA, Dorri JA. ME/CFS and Post-Exertional Malaise among Patients with Long COVID. Neurol Int. 2022;15(1):1-11. Epub 2023/01/18. doi: 10.3390/neurolint15010001. PubMed PMID: 36648965; PubMed Central PMCID: PMCPMC9844405.

67. Vernon SD, Hartle M, Sullivan K, Bell J, Abbaszadeh S, Unutmaz D, et al. Post-exertional malaise among people with long COVID compared to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Work. 2023. Epub 2023/03/14. doi: 10.3233/wor-220581. PubMed PMID: 36911963.

68. Parker M, Sawant HB, Flannery T, Tarrant R, Shardha J, Bannister R, et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. J Med Virol. 2023;95(1):e28373. Epub 2022/12/04. doi: 10.1002/jmv.28373. PubMed PMID: 36461167; PubMed Central PMCID: PMCPMC9878088.

69. Jimeno-Almazán A, Buendía-Romero Á, Martínez-Cava A, Franco-López F, Sánchez-Alcaraz BJ, Courel-Ibáñez J, et al. Effects of a concurrent training, respiratory muscle exercise, and self-management recommendations on recovery from post-COVID-19 conditions: the RECOVE trial. Journal of Applied Physiology. 2023;134(1):95-104. doi: 10.1152/japplphysiol.00489.2022. PubMed PMID: 36476156.